Table 2.

MMRM Analysis of PD Diary Outcomes: LS Mean and Placebo-Adjusted Change from Baseline by Study Visit.

Diary state (hours per day);	Placeboa	Gocovrib	Treatment difference	P-value
LS mean ± SE change from baseline
ON without (any) dyskinesiac
Week 2	1.2 ± 0.4	4.3 ± 0.4	3.2 ± 0.5	< 0.0001
Week 8	1.8 ± 0.4	4.5 ± 0.4	2.7 ± 0.6	< 0.0001
Week 12	1.7 ± 0.4	4.6 ± 0.4	2.9 ± 0.6	< 0.0001
ON with dyskinesia
Week 2	−1.2 ± 0.4	−3.7 ± 0.4	−2.6 ± 0.5	< 0.0001
Week 8	−2.1 ± 0.4	−4.0 ± 0.4	−1.9 ± 0.6	0.001
Week 12	−2.2 ± 0.4	−4.1 ± 0.4	−1.9 ± 0.6	0.002
ON with non-troublesome dyskinesia
Week 2	0.4 ± 0.3	−0.5 ± 0.3	−0.9 ± 0.4	0.02
Week 8	0.1 ± 0.3	−0.5 ± 0.3	−0.6 ± 0.5	0.24
Week 12	−0.3 ± 0.3	−0.8 ± 0.3	−0.6 ± 0.4	0.2
ON with troublesome dyskinesia
Week 2	−1.4 ± 0.3	−3.3 ± 0.3	−1.8 ± 0.4	< 0.0001
Week 8	−2.1 ± 0.3	−3.6 ± 0.3	−1.5 ± 0.4	0.0001
Week 12	−1.9 ± 0.3	−3.3 ± 0.3	−1.5 ± 0.4	0.0003
OFF
Week 2	−0.2 ± 0.2	−0.5 ± 0.2	−0.3 ± 0.2	0.17
Week 8	0.2 ± 0.2	−0.5 ± 0.2	−0.7 ± 0.3	0.01
Week 12	0.4 ± 0.2	−0.6 ± 0.2	−1.0 ± 0.3	0.0006

^aPlacebo sample size: Week 2, n = 94; Week 8, n = 87; and Week 12, n = 86.

^bGocovri sample size: Week 2, n = 94; Week 8, n = 80; and Week 12 n = 79.

^cON without (any) dyskinesia is defined as ON time with neither troublesome nor non-troublesome dyskinesia.